These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14767029)

  • 1. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.
    Böhler T; Waiser J; Schuetz M; Neumayer HH; Budde K
    Nephrol Dial Transplant; 2004 Mar; 19(3):702-13. PubMed ID: 14767029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes.
    Böhler T; Waiser J; Schütz M; Dragun D; Neumayer HH; Budde K
    Transplantation; 2004 May; 77(9):1424-32. PubMed ID: 15167602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine.
    Böhler T; Waiser J; Schütz M; Schumann B; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):482-7. PubMed ID: 14703955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.
    Böhler T; Schütz M; Budde K; Neumayer HH; Waiser J
    Int Immunopharmacol; 2007 Jan; 7(1):88-95. PubMed ID: 17161821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism.
    Böhler T; Waiser J; Schütz M; Friedrich M; Schötschel R; Reinhold S; Schmouder R; Budde K; Neumayer HH
    Transpl Int; 2000; 13 Suppl 1():S311-3. PubMed ID: 11112021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells.
    Vaessen LM; van Besouw NM; Mol WM; Ijzermans JN; Weimar W
    Transpl Immunol; 2006 Apr; 15(4):281-8. PubMed ID: 16635750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.
    Yanagawa Y; Masubuchi Y; Chiba K
    Immunology; 1998 Dec; 95(4):591-4. PubMed ID: 9893050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons.
    Quesniaux V; Fullard L; Arendse H; Davison G; Markgraaff N; Auer R; Ehrhart F; Kraus G; Schuurman HJ
    Transpl Immunol; 1999 Sep; 7(3):149-57. PubMed ID: 10608298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).
    Taylor PA; Ehrhardt MJ; Lees CJ; Tolar J; Weigel BJ; Panoskaltsis-Mortari A; Serody JS; Brinkmann V; Blazar BR
    Blood; 2007 Nov; 110(9):3480-8. PubMed ID: 17606761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mediators of FTY720 in human lymphocytes.
    Böhler T; Budde K; Neumayer HH; Waiser J
    Transplantation; 2005 Feb; 79(4):492-5. PubMed ID: 15729178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells.
    Xie JH; Nomura N; Koprak SL; Quackenbush EJ; Forrest MJ; Rosen H
    J Immunol; 2003 Apr; 170(7):3662-70. PubMed ID: 12646631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal.
    Taylor PA; Kelly RM; Bade ND; Smith MJ; Stefanski HE; Blazar BR
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1341-52. PubMed ID: 22728248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients.
    Boehler T; Schuetz M; Budde K; Neumayer H; Waiser J
    Transplant Proc; 2002 Sep; 34(6):2242-3. PubMed ID: 12270383
    [No Abstract]   [Full Text] [Related]  

  • 14. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments.
    Yopp AC; Fu S; Honig SM; Randolph GJ; Ding Y; Krieger NR; Bromberg JS
    J Immunol; 2004 Jul; 173(2):855-65. PubMed ID: 15240672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
    Hofmann M; Brinkmann V; Zerwes HG
    Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.
    Hoerning A; Köhler S; Jun C; Lu J; Fu J; Tebbe B; Dolff S; Feldkamp T; Kribben A; Hoyer PF; Witzke O
    Clin Exp Immunol; 2012 May; 168(2):251-9. PubMed ID: 22471287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells.
    Kimura T; Hasegawa T; Nakai H; Azuma T; Usui N; Sasaki T; Okada A
    Transplantation; 2003 May; 75(9):1469-74. PubMed ID: 12792499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD.
    Quesniaux VF; Menninger K; Kunkler A; Vedrine C; Bernhard M; Hedinger R; Kraus G; Schuurman HJ
    Transpl Immunol; 2000 Nov; 8(3):177-87. PubMed ID: 11147698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
    Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
    Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.